here’s a popular theory about the limitations of global pharma companies: For all their skyscrapers and strategy reviews and private jets, they’re simply too knotted up in bureaucracy to realize how many great drugs are gathering dust in their vaults.

Now, the biggest of Big Pharma is out do do something about that. Pfizer, home to nearly 100,000 employees, on Monday announced the launch of a six-person startup to develop new drugs.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • As long as the scientists (and management) of these startups are selected with the same criteria scientists are hired at big pharma companies, nothing revolutionary or innovative will ever come out of them

    • Dear Agbo, you should disclose that you work for the home team. LOL

      As I read that clinical stage drugs are the center of it, the only innovation I see here is just finding others willing to foot the bill of the clinical trials. So, no brains and scientific skills required.
      And the fact that Pfizer is not really interested to invest in them, it suggests there is a good chance that the investors will qualify as fools/suckers

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.